1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cote D`Ivoire Pharmaceuticals and Healthcare Report Q1 2016

Cote D`Ivoire Pharmaceuticals and Healthcare Report Q1 2016

  • November 2015
  • -
  • Business Monitor International
  • -
  • 58 pages

Includes 3 FREE quarterly updates

BMI View: Côte d'Ivoire's sizeable communicable disease burden means a significant proportion of healthexpenditure will remain committed to treating these conditions - in particular malaria and HIV/AIDS. In thelong-term, however, the non-communicable disease burden will grow significantly, providing moreopportunities for the sale of higher-value drugs; Roche has already made inroads into the oncology drugmarket.

Headline Expenditure Projections

? Pharmaceuticals: XOF241.62bn (USD494mn) in 2014 to XOF259.97bn (USD436mn) in 2015; +7.6%in local currency terms and -11.7% in US dollar terms. Forecast unchanged from previous quarter.

? Healthcare: XOF957.08bn (USD1.96bn) in 2014 to XOF1,040.98bn (USD1.75bn) in 2015; +8.8% inlocal currency terms and -10.7% in US dollar terms. Forecast in line with previous quarter.

Table Of Contents

Cote D`Ivoire Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Cote d`Ivoire 2013-2019) 7
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cote d`Ivoire 2011-2019) 11
Healthcare Market Forecast 12
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cote d`Ivoire 2011-2019) 14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cote d`Ivoire 2011-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cote d`Ivoire 2011-2019) 15
Pharmaceutical Trade Forecast 16
Table: Pharmaceutical Trade Data And Forecasts (Cote d`Ivoire 2013-2019) 18
Table: Pharmaceutical Trade Data And Forecasts local currency (Cote d`Ivoire 2013-2019) 18
Industry Risk Reward Index 19
Middle East and Africa Risk/Reward Index - Q1 2016 19
Côte d'Ivoire Risk/Reward Index 27
Rewards 27
Risks 28
Regulatory Review 29
Intellectual Property Issues 29
Pricing Regime 31
Market Overview 34
Healthcare Sector 35
Epidemiology 39
Table: MDG Progress 41
Competitive Landscape 43
Domestic Industry 43
Foreign Industry 44
Table: Multinational Company Activity 45
Demographic Forecast 47
Table: Population Headline Indicators (Cote d`Ivoire 1990-2025) 48
Table: Key Population Ratios (Cote d`Ivoire 1990-2025) 48
Table: Urban/Rural Population and Life Expectancy (Cote d`Ivoire 1990-2025) 49
Table: Population By Age Group (Cote d`Ivoire 1990-2025) 49
Table: Population By Age Group % (Cote d`Ivoire 1990-2025) 50
Glossary 52
Methodology 54
Pharmaceutical Expenditure Forecast Model 54
Healthcare Expenditure Forecast Model 54
Notes On Methodology 55
Risk/Reward Index Methodology 56
Index Overview 57
Table: Pharmaceutical Risk/Reward Index Indicators 57
Indicator Weightings 58

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.